dbv-technologies.com rapport :   Visitez le site

Données techniques du dbv-technologies.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte dbv-technologies.com.Actuellement, hébergé dans - et son fournisseur de services est - .

the related websites

domaine	Titre
aio.lu	home | aio technologies
dbv-technologies.com	home - dbv technologies
nds.com.pk	home - nds technologies pvt. ltd.
ams-tec.fr	home - ams technologies
amstechnologies.com	home - ams technologies ag
madwolf.com	madwolf technologies- home
eyenetics.fr	home - see fast technologies
crucible-technologies.co.uk	crucible technologies - home
inglobetechnologies.com	inglobe technologies | home
rifemachineuk.com	rife technologies - home
ei-technologies.com	ei technologies | home page
alpestechnologies.fr	home | alpes technologies
mediantechnologies.com	MEDIAN Technologies - Home
alpestechnologies.com	home | alpes technologies
motorlebentechnologies.com	home - motorleben technologies

tradingsat.com boursier.com zonebourse.com boursorama.com abcbourse.com apax.fr mypharma-editions.com gazettelabo.fr sixpoissons.canalblog.com staragora.com dumieletdusel.com midilibre.fr cuisineetvinsdefrance.com lakanal.net astroclaire.com jeujouet.com 

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Sucuri/Cloudproxy contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

languages français english leadership our pipeline viaskin ® peanut viaskin ® milk viaskin ® egg viaskin ® platform investors & media press releases events & presentations financial information sec filings amf regulated information annual reports & general meetings stock information investor faqs corporate governance board of directors audit committee compensation committee nominating committee careers contact us leadership our pipeline viaskin ® peanut viaskin ® milk viaskin ® egg viaskin ® platform investors & media press releases events & presentations financial information sec filings amf regulated information annual reports & general meetings stock information investor faqs corporate governance board of directors audit committee compensation committee nominating committee careers contact us dedicated to improving the lives of patients with food allergies and other immunological diseases merging science and technology for differentiated drug development focused on advancing transformative treatments to help patients and their caregivers dedicated to improving the lives of patients with food allergies and other immunological diseases merging science and technology for differentiated drug development focused on advancing transformative treatments to help patients and their caregivers our journey dbv technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. with this mission driving their commitment to the advancement of treatments in this field, they developed a novel class of immunotherapy that aims to activate the immune system of patients through the skin. read more for more than 15 years, we have been on a journey to advance skin immunotherapy, which merges deep science with novel manufacturing technologies, potentially offering treatment options for diseases with significant unmet medical need. today, we are focused on exploring the use of skin immunotherapy to address food allergies, a devastating condition that afflicts millions of patients. as an important milestone in our journey of developing medicines, we hope to potentially offer the first treatment for peanut allergy. tomorrow, as pioneers, we will continue to explore the boundaries of this new class of immunotherapy to develop transformative medicines for patients suffering from other conditions, including inflammatory and autoimmune diseases. patients: at the core of everything we do food allergies are serious medical conditions that occur when the body has a specific immune response to certain foods. the body’s immune response can be severe and life threatening, such as anaphylaxis. in people with food allergies, the immune system mistakenly responds to a certain food as if it were harmful. anaphylaxis is a sudden and severe allergic reaction that may cause death. read more the symptoms and severity of allergic reactions to food can be different between individuals, and can also range in severity for the same person. there are no cures for food allergies. strict avoidance of offending allergens and management of allergic reactions are the only measures that can help prevent serious health consequences for these patients. for several decades, food-allergic patients have seen limited pharmaceutical development in this field, and today have no approved treatments available. at dbv, we are committed to finding potential treatments for food allergies. for over a decade, our teams of top scientists and clinicians have been leading the development and patenting of a novel technology platform called viaskin, which may have the potential to treat food allergies. the viaskin ® platform pioneering a new class of immunotherapy through a novel technology platform, viaskin we are developing viaskin, a novel technology platform that potentially has broad applications in immunotherapy. viaskin is based on epicutaneous immunotherapy, or epit, which aims to deliver biologically active compounds to the immune system through intact skin. our potential treatment paradigm is unique: viaskin is an electrostatic patch in development that activates the immune system through the skin, which may offer easy-to-use, self-administered and non-invasive treatments to patients. epicutaneous immunotherapy (epit ® ) viaskin aims to unlock the powerful immune properties of the skin our investigational treatment is based on epicutaneous immunotherapy, or epit. this potential new class of immunotherapy works by delivering biologically active compounds to the immune system through intact skin using the viaskin platform. for those patients facing life-threatening food allergies, epit aims to desensitize them to harmful allergens by delivering compounds in small quantities into the outer layers of the skin. epit also offers a potentially strong safety profile because of how it works via the skin. safety for food-allergic patients is paramount since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening reactions, including anaphylactic shock. learn more promise and hope for the future: finding potential treatment options we are developing the viaskin technology platform to help improve the lives of patients suffering from peanut and other food allergies. programs in development include late stage clinical trials of viaskin peanut and viaskin milk, as well as pre-clinical studies of viaskin egg. viaskin ® peanut learn more viaskin ® milk learn more viaskin ® egg learn more “the ultimate goal is to change the life of the food-allergic patient …we have these patients’ lives in mind with every bit of progress that we make toward the development of viaskin.” dr. pierre-henri benhamou co-founder, chairman and chief executive officer our pipeline ongoing clinical trials dbv’s robust development program includes ongoing clinical trials of viaskin peanut and viaskin milk and pre-clinical development of viaskin egg . viaskin’s potential to unlock the immune properties of skin makes it a promising therapeutic approach beyond food allergies. dbv is investigating other areas of significant unmet medical need, including eosinophilic esophagitis (eoe), vaccines, inflammatory conditions and autoimmune diseases . learn more latest news document year terms 09/25/2018 - 7:30 am dbv technologies to present at the cantor global healthcare conference download pdf (296 kb) 2018 09/12/2018 - 7:30 am dbv technologies announces positive dsmb review of part a of phase iii study in peanut-allergic toddlers download pdf (434 kb) 2018 09/07/2018 - 6:00 pm | finance monthly information regarding the total number of voting rights and total number of shares of the company download pdf (256 kb) 2018 finance about us leadership our pipeline viaskin ® platform investors & media contact us follow us © 2018 dbv technologies. all rights reserved. dbv technologies therapies are investigational and not fda approved. terms of use

Analyse PopURL pour dbv-technologies.com

https://www.dbv-technologies.com/fr/
https://www.dbv-technologies.com/pipeline/
https://www.dbv-technologies.com/pipeline/viaskin-milk/
https://www.dbv-technologies.com/pipeline/viaskin-peanut/
https://www.dbv-technologies.com/coming-soon/
https://www.dbv-technologies.com/events
https://www.dbv-technologies.com/investor-relations/press-releases/
https://www.dbv-technologies.com/#vc_images-carousel-1-1538984688
https://www.dbv-technologies.com/wp-content/uploads/2018/09/083118-va.pdf
https://www.dbv-technologies.com/wp-content/uploads/2018/09/pr-epitope-dsmb_091218_final-1.pdf
https://www.dbv-technologies.com/investor-relations/corporate-governance/audit-committee-2/
https://www.dbv-technologies.com/investor-relations/corporate-governance/
https://www.dbv-technologies.com/investor-relations/financial-information/investor-faqs/
https://www.dbv-technologies.com/investor-relations/corporate-governance/board-of-directors/
https://www.dbv-technologies.com/wp-content/uploads/2018/09/pr_cantor_092518_final.pdf

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: dbv-technologies.com
Registry Domain ID: 96470896_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.gandi.net
Registrar URL: http://www.gandi.net
Updated Date: 2017-03-04T08:01:00Z
Creation Date: 2003-04-04T09:55:34Z
Registrar Registration Expiration Date: 2018-04-04T08:55:34Z
Registrar: GANDI SAS
Registrar IANA ID: 81
Registrar Abuse Contact Email: abuse@support.gandi.net
Registrar Abuse Contact Phone: +33.170377661
Reseller: VANKSEN
Domain Status: clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited
Domain Status:
Domain Status:
Domain Status:
Domain Status:
Registry Registrant ID:
Registrant Name: DBV TECHNOLOGIES
Registrant Organization: DBV TECHNOLOGIES
Registrant Street: 177-181, avenue Pierre Brossolette
Registrant City: Montrouge
Registrant State/Province: Ile-de-France
Registrant Postal Code: 92120
Registrant Country: FR
Registrant Phone: +33.155427878
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: domreg@vanksen.com
Registry Admin ID:
Admin Name: IP Department
Admin Organization: RDLUX SA
Admin Street: Centre Hermes Zone dActivite du Bourmicht 7 rue des Merovingiens
Admin City: Bertrange
Admin State/Province:
Admin Postal Code: 8070
Admin Country: LU
Admin Phone: +352.489090352
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email: domreg@vanksen.com
Registry Tech ID:
Tech Name: Pierre-Henri Benhamou
Tech Organization: DBV Technologies
Tech Street: 177 avenue Pierre Brossolette
Tech City: MONTROUGE
Tech State/Province: Ile-de-France
Tech Postal Code: 92120
Tech Country: FR
Tech Phone: +33.952189916
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email: 93fd7866382bf5a58c840e7015ef2f54-4456916@contact.gandi.net
Name Server: A.DNS.GANDI.NET
Name Server: B.DNS.GANDI.NET
Name Server: C.DNS.GANDI.NET
Name Server:
Name Server:
Name Server:
Name Server:
Name Server:
Name Server:
Name Server:
DNSSEC: Unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-07-21T06:26:47Z <<<

For more information on Whois status codes, please visit
https://www.icann.org/epp

Reseller Email: domreg@vanksen.com
Reseller URL: http://www.vanksen.com

Personal data access and use are governed by French law, any use for the purpose of unsolicited mass commercial advertising as well as any mass or automated inquiries (for any intent other than the registration or modification of a domain name) are strictly forbidden. Copy of whole or part of our database without Gandi's endorsement is strictly forbidden.

A dispute over the ownership of a domain name may be subject to the alternate procedure established by the Registry in question or brought before the courts.

For additional information, please contact us via the following form:

https://www.gandi.net/support/contacter/mail/

  REGISTRAR GANDI SAS

  REFERRER http://www.gandi.net

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =dbv-technologies.com

  PORT 43

  SERVER whois.gandi.net

  ARGS dbv-technologies.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME dbv-technologies.com

NSERVER

  A.DNS.GANDI.NET 173.246.98.1

  B.DNS.GANDI.NET 213.167.229.1

  C.DNS.GANDI.NET 217.70.179.1

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

  CHANGED 2017-03-04

  CREATED 2003-04-04

  EXPIRES 2018-04-04

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.